PT - JOURNAL ARTICLE AU - Kim, Gina AU - Pastoriza, Jessica M. AU - Qin, Jiyue AU - Lin, Juan AU - Karagiannis, George S. AU - Condeelis, John S. AU - Yothers, Greg AU - Anderson, Stewart AU - Julian, Thomas AU - Entenberg, David AU - Rohan, Thomas E. AU - Xue, Xiaonan AU - Sparano, Joseph A. AU - Oktay, Maja H. TI - Racial disparity in distant recurrence-free survival in localized breast cancer patients: A pooled analysis of NSABP trials AID - 10.1101/2021.12.15.21267850 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.15.21267850 4099 - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267850.short 4100 - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267850.full AB - Background Black race is associated with worse outcome in patients with breast cancer. We evaluated distant relapse-free survival (DRFS) between Black and White women with localized breast cancer who participated in NCI-sponsored clinical trials.Methods We analyzed pooled data from eight National Surgical Adjuvant Breast and Bowel Project (NSABP) trials including 9,702 women with localized breast cancer treated with adjuvant chemotherapy (AC, n=7,485) or neoadjuvant chemotherapy (NAC, n=2,217), who self-reported as Black (n=1,070) or White (n=8,632). The association between race and DRFS was analyzed using log-rank tests and multivariate Cox regression.Results After adjustment for covariates including age, tumor size, nodal status, body mass index and taxane use, and treatment (AC vs. NAC), Black race was associated with an inferior DRFS in ER-positive (HR 1.24 [95% CI 1.05-1.46], p=0.01), but not in ER-negative disease (HR 0.97 [95% CI 0.83-1.14], p=0.73), and significant interaction between race and ER status was observed (p=0.03). There was no racial disparity in DRFS among patients with pathologic complete response (pCR) (Log-rank p =0.8). For patients without pCR, black race was associated with worse DRFS in ER-positive (HR 1.67 [95% CI 1.14-2.45], p=0.01), but not in ER-negative disease (HR 0.91 [95% CI 0.65-1.28], p=0.59).Conclusion Black race was associated with significantly inferior DRFS in ER-positive localized breast cancer treated with AC or NAC, but not in ER-negative disease. In the NAC group, racial disparity was also observed in patients with residual ER-positive breast cancer at surgery, but not in those who had a pathologic complete response.Lay Summary Black women with breast cancer have worse outcome compared to White women. We investigated if this held true in the context of clinical trials which provide controlled treatment setting. Black women with cancer containing estrogen receptors (ER) had worse outcome than White women. If breast cancers did not contain ER there was no racial disparity in outcome. Moreover, we observed racial disparity in women who received chemotherapy before their cancer was removed, but only if they had cancer with ER and residual disease upon completion of treatment. If cancer disappeared upon pre-surgical chemotherapy, there was no racial disparity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported in part by grants from the Department of Health and Human Services and the National Institutes of Health (5P30CA013330, 1UG1CA189859, T32CA200561), Peter T Rowley (DOH01-ROWLEY-2019-00037), U10CA180868, UG1CA189867, and U10CA180822Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Albert Einstein College of Medicine waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors